by Gordon Hensley | Mar 26, 2019 | advocacy, Business, GOP Politics, health care, lobbying, Pharmaceutical
This more of an addenda to my last post noting how PBMs have, to their detriment, ended up on Sen. Grassley’s radar screen. Now Sen. John Cornyn (R-TX), up for reelection this cycle, has weighed in: “The whole rebate thing just looks kind of — well...
by Gordon Hensley | Feb 21, 2019 | advocacy, Business, CMS, health care, lobbying, Medicare Cuts, Pharma, U.S. House, U.S. Senate
Among the most complex but significant issues in the unfolding debate about prescription drug pricing reform is pharmacy benefit manager (PBM) rebates — or, so-called “rebates” — as many objective observers see them as kickbacks or opaque...
by Gordon Hensley | Aug 7, 2018 | Business, Media Relations, Pharma, Trump
Its not often one sees a federal agency head double the output of news releases and, according to Fierce Pharma, put out 53 policy statements in the first half of 2018 — up from just 4 during the same time period last year. That’s impressive by any...
by Gordon Hensley | Mar 10, 2018 | advocacy, Business, CMS, health care, Health Reform, Pharma, Trump
This week marked a true rarity for the Trump Administration: a coordinated, effective burst of reform-minded tough talk from three separate health policy leaders, in three consecutive days. In rat-tat-tat fashion, his HHS Secretary, CMS Administrator and FDA...
by Gordon Hensley | Mar 1, 2018 | advocacy, Business, CMS, health care, Pharma, SNF
It’s an election year. Congress has to appear to be “doing something” about the opioid epidemic engulfing communities across the U.S. The good news, it is: Senator Rob Portman (R-OH) introduced a bipartisan bill this week, the “CARA 2.0 Act of...
by Gordon Hensley | Feb 25, 2018 | advocacy, Business, lobbying, Media Relations, polling, Trump
The #1 Axios item today, “1 big thing: United States of Corporate America,” points out that “corporate social responsibility” (shorthanded as “CSR” within companies) is now one of the hottest topics in boardrooms… as corporate...